Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir + PR in Treatment-Naive Genotype 1 HCV
NCT00882908Phase 2Completed
- Sponsor
- Tibotec
- Start
- Jun 2009
- Primary completion
- Apr 2010
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of simeprevir in hepatitis C (HCV) (5 arms), sponsored by Tibotec. Primary endpoint: Sustained Virologic Response at Week 72. Started Jun 2009; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00882908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882908.